Results 11 to 20 of about 76,287 (256)
Potential role of glucagon like peptide 1 in taste receptors [PDF]
Frontiers in EndocrinologyThe perception of taste is a complex physiological process that extends far beyond the simple detection of flavor molecules, serving as a critical interface between nutrient sensing, metabolic regulation, and feeding behavior.
Jose Luis Eduardo Doval-Caballero +11 more
doaj +2 more sources
Glucagon-like peptide-1 receptor agonists in orthopaedics [PDF]
SICOT-JGlucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) help people control blood glucose and lose weight. They may also help with bone metabolism, healing fractures, keeping joints healthy, and recovering after surgery.
Mavrogenis Andreas F. +7 more
doaj +2 more sources
Glucagon-like peptide-1 analogues: An overview
Indian Journal of Endocrinology and Metabolism, 2013 Abnormalities of the incretin axis have been implicated in the pathogenesis of type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide constitutes >90% of all the incretin function.
Vishal Gupta
doaj +3 more sources
Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism [PDF]
Current Opinion in Lipidology, 2016 PURPOSE OF REVIEW: Glucagon-like peptide-1 (GLP-1) is the best known incretin hormone able to potentiate glucose-induced insulin secretion. Moreover, GLP-1 is currently under intensive investigation as a potential crucial mediator of beneficial metabolic effects after bariatric surgery, because of its eating inhibitory, antiobesity, and antidiabetes ...
Thomas A. Lutz, Elena Osto
openaire +3 more sources
Glucagon-like peptide 1 and appetite [PDF]
Trends in Endocrinology & Metabolism, 2013 Glucagon-like peptide 1 (GLP-1) and GLP-1 analogs have received much recent attention due to the success of GLP-1 mimetics in treating type II diabetes mellitus (T2DM), but these compounds may also have the potential to treat obesity. The satiety effect of GLP-1 may involve both within-meal enteroenteric reflexes, and across-meal central signaling ...
Megan J, Dailey, Timothy H, Moran
openaire +2 more sources
Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias [PDF]
Journal of ArrhythmiaBackground Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks.
Vikash Jaiswal +12 more
doaj +2 more sources
Recent Progress in Hormone Research, 2001 There is a progressive impairment in beta-cell function with age. As a result, 19 percent of the U.S. population over the age of 65 is diagnosed with type 2 diabetes mellitus (DM). Glucagon-like peptide-1 (GLP-1) is a potent insulin secretagogue that has multiple synergetic effects on the glucose-dependent insulin secretion pathways of the beta-cell ...
M E, Doyle, J M, Egan
openaire +2 more sources
Glucagon-Like Peptide-1 and Diabetes [PDF]
Experimental Diabetes Research, 2011 This special issue was focused on the role and the effects of glucagon-like peptide-1 (GLP-1) in type 2 diabetes. This gastrointestinal hormone, which is mainly secreted after meals, enhances glucose-stimulated insulin release and inhibits food intake.
openaire +2 more sources
Physiological Reports, 2017 Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone increasing postprandial insulin release. GLP‐1 also induces diuresis and natriuresis in humans and rodents. The GLP‐1 receptor is extensively expressed in the renal vascular tree in normotensive rats
Jonas Ronn +4 more
doaj +1 more source
Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells [PDF]
Endocrinology and Metabolism, 2014 BackgroundGlucagon-like peptide 1 (GLP-1), an incretin hormone well known for its glucose-lowering effect, was recently reported to exert an anabolic effect on bone. Although the exact mechanism is not known, it likely involves the GLP-1 receptor (GLP-1R)
Yun Kyung Jeon +10 more
doaj +1 more source